Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of “Buy” from Analysts

Insmed, Inc. (NASDAQ:INSM) has received an average recommendation of “Buy” from the twenty-four research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nineteen have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $203.4545.

Several research firms have commented on INSM. Barclays initiated coverage on Insmed in a research note on Tuesday, January 27th. They set an “overweight” rating and a $231.00 price objective for the company. Rothschild & Co Redburn set a $263.00 price target on Insmed in a research note on Thursday, December 4th. TD Cowen set a $241.00 price target on Insmed in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th.

Insmed Price Performance

Insmed stock opened at $148.55 on Wednesday. The company’s fifty day moving average price is $172.50 and its 200 day moving average price is $161.37. Insmed has a 1 year low of $60.40 and a 1 year high of $212.75. The stock has a market capitalization of $31.68 billion, a P/E ratio of -24.00 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insider Buying and Selling at Insmed

In other news, Director Leo Lee sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $195.90, for a total value of $14,692,500.00. Following the completion of the sale, the director directly owned 54,677 shares in the company, valued at $10,711,224.30. This represents a 57.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 19,215 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the sale, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. This represents a 5.89% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 244,857 shares of company stock valued at $44,301,247. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Several institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Insmed in the fourth quarter worth approximately $506,625,000. Vanguard Group Inc. lifted its stake in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after purchasing an additional 2,291,328 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period. Orbis Allan Gray Ltd purchased a new position in shares of Insmed during the 2nd quarter worth $153,389,000. Finally, Darwin Global Management Ltd. increased its position in shares of Insmed by 5.8% during the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after purchasing an additional 1,112,824 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.